The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts

Anesthesia and Analgesia

Volumn 88, Issue 3, 1999, Pages 559-567

  Remsen, Laura G ^a   Pagel, Michael A ^b   McCormick, Christopher I ^c   Fiamengo, Steven A ^b   Sexton, Gary ^a   Neuwelt, Edward A ^a,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ARABINOSE; ISOFLURANE; MANNITOL; METHOTREXATE; NITROUS OXIDE; PHENYLEPHRINE; PROPOFOL; PROPRANOLOL; SODIUM CHLORIDE; TRITIUM;

ANESTHESIA INDUCTION; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN TUMOR; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG PENETRATION; FEMALE; GENERAL ANESTHESIA; INHALATIONAL DRUG ADMINISTRATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; XENOGRAFT;

EID: 0033050701     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-199903000-00018     Document Type: Article

References (36)

1. Neuwelt EA, Barnett PA. Blood-brain barrier disruption in the treatment of brain tumors: animal studies. In: Neuwelt EA, ed. Implications of the blood-brain barrier and its manipulation: clinical implications. Vol 2. New York: Plenum, 1989:107-82.
2. Earth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res 1997;57:1129-36.
3. Dahlborg SA, Petrillo A, Crossen JR, et al. The potential for complete and durable response in non-glial primary brain tumors in pédiatrie patients and young adults with enhanced chemotherapy delivery. Cancer] Sei Am 1998;4:110-24.
4. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated \vith osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-90.
5. Dahlborg SA, Henner VVD, Crossen JR, et al. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sei Am 1996;2:166-74.
6. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 1995;37:17-28.
7. Miller DC, Hochberg FH, Harris NL, et al. Pathology with clinical correlations of primary central nervous system nonHodgkin's lymphoma: the Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383-97.
8. Neuwelt EA, Bamett P, McCormick CI, et al. Differential permeability of a human brain tumor xenograft in the nude rat: the impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. Clin Cancer Res 1998;4:1549-56.
9. Gumerlock MK, Neuwelt EA. The effects of anesthesia on osmotic blood-brain barrier disruption. Neurosurgery 1990;26: 268-77.
10. Roman-Goldstein S, Clunie DA, Stevens J, et al. Osmotic bloodbrain barrier disruption: CT and radionuclide imaging. Am J Neuroradiol 1994;15:581-90.
11. Vorbrodt AW, Dobrogowska DH, Tarnawaski M, Lossinsky AS. A quantitative immunocytochemical study of the osmotic opening of the blood-brain barrier to endogenous albumin. J Neurocytol 1994;23:792-800.
12. Lossinsky AS, Vorbrodt AW, Wisniewski HM. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J Neurocytol 1995;24:795-806.
13. Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 1980;238:R421-31.
14. Neuwelt EA, Barnett P, McCormick C, Frenkel E. Osmotic blood-brain barrier modification: parameters affecting drug delivery. In: Proceedings of the 5th International Meeting of the International Society for Developmental Neuroscience. Eisevier, 1984:173-9.
15. Bradbury M. The concept of a blood-brain barrier. New York, John Wiley & Sons, 1979:352-4.
16. Rapoport SI. Blood-brain barrier in physiology and medicine. New York, Raven, 1976.
17. 133xenon for measurement of regional cerebral blood flow (rCBF) during halothane, enflurane and isoflurane anesthesia in humans. Anesthesiology 1985;63:391-4.
18. Arbit E, DiResta GR, Bedford RF, et al. Intraoperative measurement of cerebral and tumor blood flow with laser-Doppler flowmetry. Neurosurgery 1989;24:166-70.
19. Fox J, Gelb AW, Enns J, et al. The responsiveness of cerebral blood flow to changes in arterial carbon dioxide is maintained during propofol-nitrous oxide anesthesia in humans. Anesthesiology 1992;77:453-6.
20. Stephen H, Sonntag H, Schenk HD, et al. Effects of disoprivan on cerebral blood flow, cerebral oxygen consumption and cerebral vascular reactivity. Anaesthesist 1987;36:60-5.
21. Barnett PA, Roman-Goldstein S, Ramsey F, et al. Differential permeability and quantitative MR imaging of a human lung carcinoma brain xenograft in the nude rat. Am J Pathol 1995; 146:436-49.
22. Kroll R, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998;42:1083-100.
23. Boucher Y, Leuning M, Jain RD. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996,6:4264-6.
24. Boucher Y, Salehi H, Witwer B, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 1997;75:829-36.
25. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid rumors: implications for vascular collapse. Cancer Res 1992;52:5110-4.
26. Huffman BB, Lefkowitz RJ. Adrenergic receptor antagonists. In: Gilman AG, ed. Goodman and Gilmans' the pharmacological basis of therapeutics. New York: Pergamon, 1990:221-43.
27. Eger El II. Isoflurane: a review. Anesthesiology 1981;55:559-76.
28. Gomez Sainz JJ, Elex Puru Camiruaga JA, Gemandez Cano F, de la Herran JL. Effects of isoflurane on intraventricular pressure in neurosurgical patients. Br J Anaesth 1988;61:347-9.
29. Adams RYV, Cucchiara RF, Gronert GA, et al. Isoflurane and cerebrospinal fluid pressure in neurosurgical patients. Anesthesiology 1981;4:97-9.
30. Todd MM, Weeks J. Comparative effects of propofol, pentobarbital, and isoflurane on cerebral blood flow and blood volume. J Neurosurg Anesth 1996;8:296-303.
31. Fulton B, Sorkin EM. Propofol: an overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995,0:636-57.
32. Smith I, White PF, Nathanson M, Gouldson R. Propofol: an update on its clinical use. Anesthesiology 1994;81:1005-43.
33. Ravussin P, Tempelhoff R, Modica PA, Bayer-Berger MM. Propofol vs. thiopental-isoflurane for neurosurgical anesthesia: comparison of hemodynamics, CSF pressure, and recovery. J Neurosurg Anesth 1991;3:85-95.
34. Drummond JC, Shapiro HM. Cerebral physiology. In: Milfer RD, ed. Anesthesia. New York: Churchill Livingstone, 1994: 689-730.
35. Moss E, McDowal DG. ICP increases with 50% nitrous oxide and oxygen in severe head injuries during controlled ventilation. Br J Anaesth 1979,1:757-61.
36. Eng C, Lam AM, Mayberg TS, et al. The influence of propofol with and without nitrous oxide on cerebral blood flow velocity and CO2 reactivity in humans. Anesthesiology 1992;77:872-9.